18:25 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant

Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that two patients developed neutralizing antibodies to its CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest dose cohort of a Phase I/II trial...
23:12 , Jun 18, 2018 |  BC Extra  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant, crater stock

Catalyst Biosciences Inc. (NASDAQ:CBIO) fell $16.14 (64%) to $9.11 Monday when it reported that two patients developed neutralizing antibodies to CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304 ). The company said it will continue to explore...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Catalyst Biosciences, Targacept deal

Targacept and Catalyst will merge, with Catalyst shareholders owning about 65% of the combined company and Targacept shareholders owning the remaining portion. The resulting company expects to have $40 million at closing. Targacept will provide...
08:00 , Feb 13, 2014 |  BC Innovations  |  Targets & Mechanisms

A RIPping target in Gaucher's disease

Enzyme-replacement therapies are highly effective for most patients with Gaucher's disease but do little for those with the neurological childhood forms of the disease. Now, an Israeli and U.K. team has unlocked the mechanism of...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Catalyst Biosciences, Isu Abxis deal

Catalyst and Isu partnered to develop Catalyst's FIX-NG ( CB 2679d ) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant Factor IX protein is in preclinical testing, with...
07:00 , Oct 14, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down $0.45 to $5.15 last week after FDA accepted for review an NDA for Bunavail buprenorphine naloxone to treat opioid dependence. The company expects a decision by...
23:42 , Oct 9, 2013 |  BC Extra  |  Company News

Catalyst, Isu Abxis partner for Catalyst's Factor IX

Catalyst Biosciences Inc. (South San Francisco, Calif.) and Isu Abxis Co. Ltd. (KOSDAQ:086890) partnered to develop Catalyst's FIX-NG (CB 2679d) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...